FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Siegel Jonathan B. (Last) (First) (Middle) C/O JAGUAR HEALTH, INC. 200 PINE STREET, SUITE 400					Issuer Name and Ticker or Trading Symbol Jaguar Health, Inc. [JAGX] Date of Earliest Transaction (Month/Day/Year) 05/18/2021							eck all applic	cable) or (give title	Person(s) to Is 10% C Other below)	wner (specify
(Street) SAN FRANCI	SAN CA 94104 FRANCISCO				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			ansactio	2A. Deemed Execution Date,		3. Transaction	4. Secur Dispose 5)	rities Acquired Of (D) (Ins	ed (A) or etr. 3, 4 and	5. Amount Securities Beneficial Owned FReported Transact	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	itle of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, urity or Exercise (Month/Day/Year) if any		Code	5. Number of ode (Instr. Derivative			Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock option (right to buy) ⁽¹⁾	\$1.24	05/18/2021 ⁽²⁾		A		72,750		(3)	05/18/2031	Common Stock	72,750	\$0	72,750	D	
Restricted stock units ⁽¹⁾	(4)	05/18/2021 ⁽²⁾		A		36,400		(5)	(5)	Common Stock	36,400	\$0	36,400	D	

Explanation of Responses:

- 1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.
- 2. The option and restricted stock unit grants were approved by the issuer's board of directors on May 18, 2021.
- 3. The options will vest in full on May 18, 2022, the first anniversary of the grant date, so long as the director continues to serve on the board of directors of the issuer.
- 4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 5. The restricted stock units vest in full on May 18, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

/s/ Jonathan B. Siegel

05/19/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.